ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Zivo Bioscience, Inc.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$6.80+0.30 (+4.62%)
Close on Oct 19, 2026
- Market cap
- $25.96M
- P/E (TTM)
- –
- Dividend yield
- –
Zivo Bioscience statistics
Financials through Sep 30, 2025, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Market Cap | $26.44M | $166.30M |
| Enterprise Value | $26.40M | $88.19M |
| PS Ratio | 126.50 | 3.65 |
Enterprise value
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| EV / Sales | 126.29 | 2.51 |
Income (trailing twelve months)
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Revenue | $209.03K | $58.34M |
| Gross Profit | $66.21K | $105.94M |
| Operating Income | -$8.46M | -$21.40M |
| Net Income | -$8.49M | -$22.46M |
| EBITDA | -$8.46M | -$16.91M |
| EPS (Diluted) | -$2.27 | -$0.83 |
Margins
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Gross Margin | 31.7% | 52.9% |
| Operating Margin | -4045.6% | -44.0% |
| Profit Margin | -4059.7% | -40.2% |
| EBITDA Margin | -4045.6% | -30.2% |
Returns
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Return on Assets (ROA) | -1608.6% | -40.9% |
Growth
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 164.5% | 5.96% |
Balance sheet
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $57.22K | $61.43M |
| Total Debt | $11.66K | $118.52M |
| Net Cash (Debt) | $45.56K | $15.35M |
| Net Cash Per Share | $0.01 | $0.66 |
| Equity (Book Value) | -$3.29M | $49.09M |
| Book Value Per Share | -$0.85 | $1.37 |
| Tangible Book Value | -$3.29M | $23.52M |
| Working Capital | -$3.33M | $76.81M |
Financial position
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Current Ratio | 0.08 | 3.34 |
| Quick Ratio | 0.02 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.08M | -$12.35M |
Efficiency
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 0.40 | 0.39 |
| Revenue Per Employee | $29.86K | $404.87K |
| Profits Per Employee | -$1.21M | -$703.34K |
| Employee Count | 7 | 74 |
Dividends and yields
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -32.1% | -23.3% |
Shares
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 3,888,600 | 58,127,000 |
| Shares Change (QoQ) | 0.40% | 0.54% |
| Float | 1,348,160 | 49,136,700 |
| Shares Held by Insiders | 65.3% | 11.6% |
| Shares Held by Institutions | 0.11% | 59.4% |
Scores
| Measure | Zivo Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | -412.51 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Zivo Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.